Invest In Greece Because The Turnaround Has Already Started [View article]
The normal retirement age in Greece is 65 to 67 years and the early retirement with 30 years work is 58 for some categories. Only in a very few other categories, like the law enforcement agency, is reduced around to 50 years.
Not so long ago, we had for Greece the scenic picture of Mykonos with Athens as a capital and Acropolis with donkeys around as the main public transit. Now we have discovered a nation of lazy crooks. We prefer to live in myths and stereotypes...
Is This Oil-Weighted Energy Producer Overvalued After The Recent Price Surge? [View article]
Thank you VD.
What I like in your articles and responces, is that you call a spade a spade, without any "beating about the bush". I would also like to see a seperate article about Tuscany from you.
I have sold the half of my position in Surge at $4.91...I don't disagree with you, it's far from being overvalued but I took some good profits, which has been made in a short time. For the rest 50%, I'm waiting to see how things turn out.
Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals [View article]
The CEO said in several CC that it's not his intention to sell the company, but they are in late discussions with big pharmas for a partnership. He referred to late stage discussions recently in BioCentury Publications Future Leaders in the Biotech Industry Conference, in April 5, the link with his CC is still available I think.
Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals [View article]
To Inovio's stuff, I think could be added Mark L. Bagarazzi, M.D. the Chief Medical Officer of Inovio Pharmaceuticals. Dr. Bagarazzi leads worldwide clinical development and regulatory activities for Inovio's next-generation vaccines for the treatment and prevention of influenza, HIV, other infectious diseases and cancers. He joined Inovio from Merck & Co., where he was Director of worldwide regulatory affairs for vaccines and biologics. He also worked onMerck's ZOSTAVAX(R), the leading vaccine for shingles. He was responsible for global regulatory activities related to Merck vaccine candidates for the prevention of HIV/AIDS. He successfully led the regulatory process through to FDA approval of RotaTeq(R), Merck's vaccine against rotavirus.
Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals [View article]
As there is no reason for a reverse split, to wait for it will create a missing opportunity, when another certain positive catalyst like the HIV-1 PENNVAX peer reviewed scintific paper is coming in less than a month and half.
Paulson's Big Bets Have Been The Ultimate Contrarian Indicators For 2 Years Now [View article]
I still own both Surge and Tuscany, I added in my position in Tuscany recently too. I haven't lock any profits from Surge yet, as todays rebound, in terms of volume and pps increase is technically very promising.
I hope VD will write a new article about Tuscany soon because from his article, many things have changed in this company.
A Comprehensive Overview Of Active Electroporation Cancer Trials [View article]
The bottom line is that you did not know "Inovio biomedical" and "Inovio Pharmaceuticals" under the leadership of Dr. J. Kim, are two different companies. All the rest are explained very well by "Kyle_Ramer" , above.
A Comprehensive Overview Of Active Electroporation Cancer Trials [View article]
Well... I understand it will be a long post...but it's only the 6 last months clinical trials of Inovio, with the use of its Electroporation Devices. All successful as you can see:
1. May 14, 2013 Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study/ Polyvalent Vaccine Design Stimulates Significant Antibody and T-Cell Responses with 100% Survival Against Multiple Families of Most Lethal Virus Known to Man.
2. Apr 18, 2013 Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study Broadly targeted SynCon® H1N1 vaccine induces protective antibodies comparable to current seasonal vaccine against currently circulating influenza strain.
3. Jan 9, 2013 Inovio Pharmaceuticals to Initiate Clinical Trial for its Hepatitis C Therapeutic Vaccine (INO-8000) Later this Year Phase I/IIa Trial Follows Preclinical Study Demonstrating for First Time that a Multi-Antigen HCV Vaccine Can Generate Potent T-Cell Response in Liver.
4. Dec 10, 2012 Inovio's Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses. Clinical Trial with Universal Vaccine Increases Response Rate of Subjects Generating Infection-Preventing Antibodies by 100% in Population Most at Risk for Flu Deaths.
5. Dec 6, 2012 Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial.
6. Nov 26, 2012 Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study.
7. Nov 12, 2012 Inovio Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential to Clear HBV in Liver. Inovio Advances New Disease Therapy, Where 400 Million Patients Lack Effective Treatment.
I think this is enough to reconsider the phrase "history of failure", for Inovio Pharmaceuticals. But, if I'm wrong and this is not enough, I can provide another 6 months successful clinical trials...
Value And Growth Go Hand In Hand In The Drilling Market [View article]
President and CEO W. Dawson to sell the entire company, as he did with his previous companies, why you think is not a option? Mark that he bought around 2 million shares recently in the open market.
Surge Energy: The Baby Has Obviously Been Thrown Out With The Bathwater [View article]
Value Digger, you had insisted in Surge, repeating many times that you were buying while this stock looked like a "falling knife" and none had the guts to say 'I'm buying", even if he did so.
Invest In Greece Because The Turnaround Has Already Started [View article]
Only in a very few other categories, like the law enforcement agency, is reduced around to 50 years.
Not so long ago, we had for Greece the scenic picture of Mykonos with Athens as a capital and Acropolis with donkeys around as the main public transit. Now we have discovered a nation of lazy crooks.
We prefer to live in myths and stereotypes...
Is This Oil-Weighted Energy Producer Overvalued After The Recent Price Surge? [View article]
What I like in your articles and responces, is that you call a spade a spade, without any "beating about the bush".
I would also like to see a seperate article about Tuscany from you.
I have sold the half of my position in Surge at $4.91...I don't disagree with you, it's far from being overvalued but I took some good profits, which has been made in a short time. For the rest 50%, I'm waiting to see how things turn out.
Is This Oil-Weighted Energy Producer Overvalued After The Recent Price Surge? [View article]
Which stock did you buy after selling most of your shares in Surge?
Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals [View article]
He referred to late stage discussions recently in BioCentury Publications Future Leaders in the Biotech Industry Conference, in April 5, the link with his CC is still available I think.
Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals [View article]
Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals [View article]
Paulson's Big Bets Have Been The Ultimate Contrarian Indicators For 2 Years Now [View article]
I hope VD will write a new article about Tuscany soon because from his article, many things have changed in this company.
Paulson's Big Bets Have Been The Ultimate Contrarian Indicators For 2 Years Now [View article]
A Comprehensive Overview Of Active Electroporation Cancer Trials [View article]
A Comprehensive Overview Of Active Electroporation Cancer Trials [View article]
I understand it will be a long post...but it's only the 6 last months clinical trials of Inovio, with the use of its Electroporation Devices. All successful as you can see:
1. May 14, 2013
Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study/
Polyvalent Vaccine Design Stimulates Significant Antibody and T-Cell Responses with 100% Survival Against Multiple Families of Most Lethal Virus Known to Man.
2. Apr 18, 2013
Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
Broadly targeted SynCon® H1N1 vaccine induces protective antibodies comparable to current seasonal vaccine against currently circulating influenza strain.
3. Jan 9, 2013
Inovio Pharmaceuticals to Initiate Clinical Trial for its Hepatitis C Therapeutic Vaccine (INO-8000) Later this Year
Phase I/IIa Trial Follows Preclinical Study Demonstrating for First Time that a Multi-Antigen HCV Vaccine Can Generate Potent T-Cell Response in Liver.
4. Dec 10, 2012
Inovio's Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses.
Clinical Trial with Universal Vaccine Increases Response Rate of Subjects Generating Infection-Preventing Antibodies by 100% in Population Most at Risk for Flu Deaths.
5. Dec 6, 2012
Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial.
6. Nov 26, 2012
Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study.
7. Nov 12, 2012
Inovio Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential to Clear HBV in Liver.
Inovio Advances New Disease Therapy, Where 400 Million Patients Lack Effective Treatment.
I think this is enough to reconsider the phrase "history of failure", for Inovio Pharmaceuticals. But, if I'm wrong and this is not enough, I can provide another 6 months successful clinical trials...
Inovio Pharmaceuticals: Why Best Therapeutic Vaccine Award In 2013? [View article]
Add to the insiders purchases the 60,000 shares, one month ago, of the CMO Dr. Bagarazzi.
Invest In Greece Because The Turnaround Has Already Started [View article]
Surge Energy: The Time Has Come For Investors To Get Greedy [View article]
Value And Growth Go Hand In Hand In The Drilling Market [View article]
Surge Energy: The Baby Has Obviously Been Thrown Out With The Bathwater [View article]
CONGRATS.